A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
about
Anti-RhD immunoglobulin in the treatment of immune thrombocytopeniaRozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.The emerging importance of α-L-fucose in human breast cancer: a review.Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D.Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Lessons learnt from many years of experience using anti-D in humans for prevention of RhD immunization and haemolytic disease of the fetus and newborn.Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodiesCombined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model.Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.
P2860
Q33385974-5473B838-B1C9-4997-9AD1-82B577F837A1Q33407831-675E0699-35D1-4D0C-9E42-084A04F17EFDQ33911286-2FC0DE0D-9258-4F26-BF3E-46E12853FA7DQ34323394-F645D353-EF06-4B02-9493-81B5739ABD28Q35172546-D33E7C81-514C-4D8F-86B0-64321124CB22Q35262648-70BD961E-F424-4D37-9A36-BD7C3F531C09Q37064733-779AC716-DECC-4AD5-B4D4-BA56305DAE1CQ37252443-7FEAB106-6A13-4681-B4DB-D3B698F1B92FQ37311301-DABDC951-E11A-434D-BA49-EA421DCCF6C7Q38718049-793EB1B9-BFFB-4078-9DCA-DBC6D6FB19FFQ42173120-6E38EF80-1B60-4522-B3A6-17984D6AF5BEQ42869354-340458F9-CF4E-4C85-A901-29010B3A1BB5Q43234219-10E63C41-4AB3-4B6B-97F9-866D04E5F0C4Q52648918-EFF71013-96C6-4846-9176-037C4065EB18
P2860
A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@en
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@nl
type
label
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@en
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@nl
prefLabel
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@en
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@nl
P2093
P2860
P1476
A human anti-D monoclonal anti ...... polyclonal anti-D antibodies.
@en
P2093
Christophe de Romeuf
Dominique Bourel
Dominique Notelet
Eric Guemas
Frédéric Dhainaut
Jean-François Prost
Jean-Luc Teillaud
Léna Massad
Roland Beliard
Tony Waegemans
P2860
P304
P356
10.1111/J.1365-2141.2008.06985.X
P407
P577
2008-02-12T00:00:00Z